Three patients with aplastic anaemia following chloroquine therapy are described. In two, chloroquine had been administered in large doses over a long period. One of them subsequently developed acute myeloblastic leukaemia.'The third received only a small dose and pancytopenia with aplasia followed three weeks after ingestion of the drug. The mechanism(s) of chloroquine-induced marrow injury is not known. A parallel to chloramphenicol-induced blood dyscrasias is drawn, but remains unproved.
Summary
Three patients with aplastic anaemia following chloroquine therapy are described. In two, chloroquine had been administered in large doses over a long period. One of them subsequently developed acute myeloblastic leukaemia.'The third received only a small dose and pancytopenia with aplasia followed three weeks after ingestion of the drug. The mechanism(s) of chloroquine-induced marrow injury is not known. A parallel to chloramphenicol-induced blood dyscrasias is drawn, but remains unproved.
BONE marrow aplasia with pancytopenia or some form of bone marrow injury, resulting in isolated cytopenias can result from many drugs in current use.
A positive history of drug exposure can be obtained in more than 66% of patients with aplastic anaemia (Vincent and de Gruchy, 1967) . Chloramphenicol, phenylbutazone, mephenytoin, sulphonamides and gold compounds are the drugs most commonly reported as causing marrow aplasia.
It is well known that certain agents capable of producing aplastic anaemia in man can also cause leukaemia (Dougan and Woodliff, 1965) . The development of leukaemia in the course of aplastic anaemia is of considerable interest. Aplastic anaemia without known cause may be premonitory of acute leukaemia (Saarini and Linmann, 1973; Nagaratnam, 1976) or aplastic anaemia with a known cause may develop into acute leukaemia. Chloramphenicol is a commonly cited cause of acquired aplastic anaemia, and case reports of acute myelocytic leukaemia following chloramphenicol-induced aplasia have been published (Mukherji, 1957; Brauer and Damashek, 1969 (Fig. la, b) . There was no history of jaundice or any prolonged illness and he had not been on any prolonged drug therapy. He had never handled insecticides.
On admission he was extremely pale and there was systolic murmur in the pulmonary area. The haemoglobin was 2-7 g/dl, and white cell count was 3-6 x 109/l. He was transfused with 3 pints of blood.
In January 1976 he presented with bleeding gums, weakness and occasional vomiting. Haematological investigations revealed a haemoglobin of 2-3 g/dl, white blood cell count of 4-2 x 109/l, and a differential of 1 18 x 109/l neutrophils, 2-92 x 109/l lymphocytes, and 0-08 x 109/l monocytes. The platelets numbered 120 x 109/l. The ESR (Westergren) 110 mm in 1 hr. Reticulocyte count 0-2/mm3, bleeding time >10 min and clotting time 3 min. He was given blood transfusions.
He was transferred to the General Hospital Colombo, and on admission he was extremely anaemic with extensive dermal haemorrhages. There were haemorrhages in the ocular fundi. Haemoglobin level was 3-5 g/dl, haematocrit 21%, white cell count 5 0 x 109/l, platelets 21-0 x 109/l, bleeding time of >20 min and serum bilirubin of 10 ng/dl. Peripheral blood film was negative for malarial parasites. A marrow aspirate showed a very hypocellular marrow. Iliac crest biopsy showed an extremely fatty marrow with very little haemopoietic tissue (Fig. 2) . His B12 level was 230 pg/ml; and folate 4-2 ng/ml. He was treated with high doses of steroids, and blood transfusions. He died 3 months later.
Comment: This young male had had a short course of chloroquine. He had not taken any other drugs. Anaemia with neutropenia followed three weeks' ingestion of the drug; and marrow later revealed aplasia.
Discussion
Chloroquine had been taken by all three patients, two of whom had taken it in large doses over a long period, and the third in a relatively small dose. All developed aplasia of the bone marrow. There was no history of any other drug or chemical agent that could be incriminated. All three patients were from areas endemic for malaria. Neva (1967) stressed the importance of making a clear distinction between potential hazards of longterm treatment of arthritis and collagen diseases with chloroquine, in contrast to a more limited use of the drug as an anti-malarial. He feels that much confusion can result from papers dealing with chloroquine toxicity if it is not made clear that malarial prophylaxis requires the drug in doses of 05 g weekly and acute malaria requires it in a dose of 2-5 g daily for two to three days. However, in contrast to this, chloroquine-induced ocular, otic and muscular damage followed when the drug was given in doses of 025-1 g daily for 4-6 months.
The relationship between chloroquine and bone marrow injury is still uncertain. Agranulocytosis is a blood dyscrasia frequently reported as being due to chloroquine and hydroxychloroquine (Propp and Stillman, 1976; Polana, Cats and Van Olden, 1965; McDuffie, 1965) . According to Propp and Stillman (1967) the manufacturers of hydroxychloroquine have had in their files some unpublished cases of blood dyscrasias associated with this drug: one of aplastic anaemia (fatal), one of thrombocytopenia (fatal), one of agranulocytosis and one of aplastic anaemia.
The mechanism of bone marrow injury due to drugs and other agents remains unclear. Perhaps, in this respect, chloramphenicol is a drug that has been most extensively studied. According to Yunis and Bloomberg (1964) and Yunis (1975) , two main forms of aplasia following chloramphenicol therapy could be identified. In one, the onset is acute, it is dose-related and frequently the marrow is normocellular but exhibits vacuolization of erythroblasts and granulocytic precursors. There is moderate anaemia and reticulocytopenia. Unless the dosage is remarkably high, this type of aplasia is reversible when the drug is discontinued (Brauer and Damashek, 1969) . The other is of late onset and may not be dose-related. There is hypoplasia or severe aplasia of the marrow and the manifestations of marrow depression occur weeks or months after the drug has been stopped. In the former, the current evidence is that the reversible bone marrow suppression following chloramphenicol results from inhibition of mitochondrial protein synthesis. In the other, there is a strong suggestion of a stem cell lesion. The rare occurrence of this complication is suggestive of individual predisposition.
It is tempting to use some of these signs to explain the findings in the three patients following the use of chloroquine. It would appear that patients 1 and 2 belong to the dose-related categories. In patient 1, the primary effect of the drug was anaemia, it was only after the further use of the drug months later that the condition was aggravated. In patient 3, there is no relationship to dose and he had severe aplasia which occurred three weeks after the drug had been administered.
